(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
----------
AIM - WINNERS
----------
Supreme PLC, up 15% at 126.24 pence, 12-month range 87p-135p. The manufacturer and distributor of battery, lighting and vaping products says its interim profit jumps, and upgrades annual guidance after strong third-quarter-to-date trading. In the six months to September, revenue rises 63% on-year to GBP105.1 million from GBP64.6 million. Pretax profit nearly triples to GBP12.3 million from GBP4.4 million. It raises its interim payout to 1.5p per share from 0.8p the prior year. The firm says its second half has "begun very well", with growth reported across all divisions. It now expects financial 2024 revenue to be between GBP210 and GBP225 million, which is up from March's guidance of GBP195 to GBP205 million. Adjusted earnings before interest, tax, depreciation and amortisation are forecast between GBP32 to GBP35 million, compared to the prior range of GBP28 to GBP30 million.
----------
Fusion Antibodies PLC, up 17% at 4.05p, 12-month range 3.02p-70p. The contract research organisation providing discovery, design and optimisation services for therapeutic antibodies to the healthcare market signs a collaboration agreement with the US National Cancer Institute. The collaboration will see the NCI use the firm's OptiMAL to discover novel antibodies in targets selected by NCI. "We are delighted to have been able to secure a partner with the expertise of NCI to provide validation to the technology without Fusion being required to commit significant resource to the project," says CEO Adrian Kinkaid. OptiMAL is a new mammalian antibody library, which Fusion says eliminates the need for platform switching and reformatting common with other approaches.
----------
AIM - LOSERS
----------
Totally PLC, down 24% at 6.69p, 12-month range 6p-38p. The healthcare services provider reports a disappointing set of interim results for the six months to September 30. Totally says revenue drops to GBP55.8 million from GBP70.3 million year-on-year, while the firm swings to a pretax loss of GBP1.9 million from GBP1.0 million profit. The firm blames the previously-outlined "crisis" faced by the UK National Health Service for the lower revenue, given the loss of North West London contracts. "As the contracts came to the end of their contracted period, and despite previous assertions that we would retain the contracts, the ICB allowed the contracts to end. We were unable to terminate all costs immediately at that point but have since undertaken a significant cost review to remove costs related to those contracts as well as other costs which are not critical to the day to day running of the business," says Chair Bob Holt. Bolt will step down from the end of the year,,with Simon Stilwell to take his place from January 1. Stilwel was previously CEO of Bonhill Group PLC, and Liberum, which he co-founded, and currently is a non-executive director at Gresham House PLC.
----------
By Elizabeth Winter, Alliance News deputy news editor
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Fusion Antibody (FAB)
Totally (TLY)
Supreme Plc (SUP)